Pyxis Oncology Inc [NASDAQ: PYXS] closed the trading session at $3.82.
The stocks have a year to date performance of 112.22 percent and weekly performance of -10.75 percent. The stock has been moved at -2.05 percent over the last six months. The stock has performed 8.83 percent around the most recent 30 days and changed 4.66 percent over the most recent 3-months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If compared to the average trading volume of 528.65K shares, PYXS reached to a volume of 4249450 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Pyxis Oncology Inc [PYXS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PYXS shares is $10.29 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PYXS stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Stephens have made an estimate for Pyxis Oncology Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on November 08, 2024. While these analysts kept the previous recommendation, Stifel raised their target price to Buy. The new note on the price target was released on August 08, 2024, representing the official price target for Pyxis Oncology Inc stock. Previously, the target price had yet another raise to $10, while Jefferies analysts kept a Buy rating on PYXS stock.
The Average True Range (ATR) for Pyxis Oncology Inc is set at 0.32, with the Price to Sales ratio for PYXS stock in the period of the last 12 months amounting to 14.07. The Price to Book ratio for the last quarter was 1.48, with the Price to Cash per share for the same quarter was set at 2.46.
PYXS stock trade performance evaluation
Pyxis Oncology Inc [PYXS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -10.75. With this latest performance, PYXS shares gained by 8.83% in over the last four-week period, additionally sinking by -2.05% over the last 6 months – not to mention a rise of 165.28% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PYXS stock in for the last two-week period is set at 46.74, with the RSI for the last a single of trading hit 41.16, and the three-weeks RSI is set at 49.21 for Pyxis Oncology Inc [PYXS]. The present Moving Average for the last 50 days of trading for this stock 3.71, while it was recorded at 4.11 for the last single week of trading, and 4.06 for the last 200 days.
Pyxis Oncology Inc [PYXS]: An insightful look at the core fundamentals
Pyxis Oncology Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.33 and a Current Ratio set at 7.33.
Earnings per share (EPS) analysis for Pyxis Oncology Inc [PYXS] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PYXS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pyxis Oncology Inc go to 34.60%.
Pyxis Oncology Inc [PYXS]: Institutional Ownership
There are presently around $54.52%, or 72.25%% of PYXS stock, in the hands of institutional investors. The top three institutional holders of PYXS stocks are: DEEP TRACK CAPITAL, LP with ownership of 4.18 million shares, which is approximately 8.1578%. LAURION CAPITAL MANAGEMENT LP, holding 3.86 million shares of the stock with an approximate value of $$12.78 million in PYXS stocks shares; and LAURION CAPITAL MANAGEMENT LP, currently with $$9.22 million in PYXS stock with ownership which is approximately 5.4317%.
